Table 1.
Baseline Patient Characteristics
| Characteristics | N = 9 |
|---|---|
| Age, y | |
| Median | 58 |
| Range | 49–73 |
| Sex, n (%) | |
| Male | 4 (44) |
| Female | 5 (56) |
| Race, n (%) | |
| White | 7 (78) |
| Asian | 0 (0) |
| Other | 2 (22) |
| Histology, n (%) | |
| Adenocarcinoma | 9 (100) |
| ECOG performance status, n (%) | |
| 0 | 6 (67) |
| 1 | 3 (33) |
| Smoking status, n (%) | |
| Never | 6 (67) |
| Light (≤10 pack-y) | 2 (22) |
| Heavy (>10 pack-y) | 1 (11) |
| Brain metastases, n (%) | |
| Present | 8 (89) |
| Absent | 1 (11) |
| RET testing, n (%) | |
| FISH | 3 (33) |
| Next-generation sequencing | 6 (66) |
| Previous RET MKIs, n (%) | |
| Yes | 3 (33) |
| No | 6 (66) |
| Previous lines of therapy, n (%) | |
| Median | 3 |
| Range | 1-5 |
ECOG, Eastern Cooperative Group; FISH, fluorescence in situ hybridization; MKI, multikinase inhibitor.